Biphasic Mesothelioma: Clinical Trials

2 trials for Biphasic Mesothelioma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 completed. 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11Active not recruiting 1
Phase 21Completed 1

Follow Biphasic Mesothelioma: new trials by email Literature Review of Biphasic Mesothelioma trials Research Report on Biphasic Mesothelioma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
Atezolizumab, Cisplatin, Extrapleural Pneumonectomy - Biphasic Mesothelioma, Epithelioid Mesothelioma
Phase 1Active not recruitingNational Cancer Institute (NCI)282018-07-162026-11-13
Pembrolizumab in Treating Patients With Malignant Mesothelioma
Pembrolizumab, Laboratory Biomarker Analysis, Pharmacogenomic Study - Biphasic Mesothelioma, Epithelioid Mesothelioma
Phase 2CompletedUniversity of Chicago652015-03-312026-05-08

Narrower conditions

Mesothelioma, Malignant (2)  ·  Solitary Fibrous Tumor, Pleural (1)

Broader conditions

Adenoma (2)  ·  Lung Diseases (2)  ·  Lung Neoplasms (2)  ·  Mesothelioma (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Neoplasms by Site (2)  ·  Neoplasms, Glandular and Epithelial (2)  ·  Neoplasms, Mesothelial (2)  ·  Pleural Neoplasms (2)  ·  Respiratory Tract Diseases (2)  ·  Respiratory Tract Neoplasms (2)  ·  Thoracic Neoplasms (2)  ·  Neoplasms, Connective Tissue (1)  ·  Neoplasms, Connective and Soft Tissue (1)

Interventions

1,2-diaminocyclohexaneplatinum II citrate (1)  ·  Cisplatin (1)  ·  Pemetrexed (1)  ·  Pharmacogenomic Testing (1)  ·  Platinum (1)  ·  Radiation (1)  ·  Radiotherapy (1)  ·  atezolizumab (1)  ·  pembrolizumab (1)

Sponsors

National Cancer Institute (NCI) (1)  ·  University of Chicago (1)

Countries

United States (2)

Top investigators

Anne S Tsao (1)  ·  Hedy Kindler (1)

NIH funding

P30CA014599 (1), U10CA180888 (1)